Add to ORKGterifl unomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 tria
Introduction: We have different treatment alternatives for relapsing-remitting multiple sclerosis–RR...
BACKGROUND: The monoclonal antibody ublituximab enhances antibody-dependent cellular cytolysis and p...
Background: Disease-modifying therapy is the standard treatment for patients with multiple sclerosis...
Teriflunomide is an oral disease-modifying therapy approved for treatment of relapsing or relapsing-...
The article discusses the prospects for the use of the new drug teriflunomide for the treatment of p...
AbstractPurposeThe purpose was to summarize US prescribing information for teriflunomide in the trea...
BACKGROUND: Teriflunomide is a new oral disease-modifying therapy for relapsing forms of multiple sc...
Teriflunomide is a new oral disease-modifying therapy for relapsing forms of multiple sclerosis.We c...
Miller, Aaron E O'Connor, Paul Wolinsky, Jerry S Confavreux, Christian Kappos, Ludwig Olsson, Tomas ...
The landscape of the treatment of relapsing–remitting multiple sclerosis is changing fast. Several o...
Teriflunomide is a once-daily oral agent that has been licensed in the EU since August 2013 for the ...
Teriflunomide is a once-daily oral immunomodulator approved for the treatment of relapsing-remitting...
Antonios Bayas,1 Mathias Mäurer2 1Department of Neurology, Klinikum Augsburg, Augsburg, Germany...
Background Therapeutic options for children with multiple sclerosis are scarce. Teriflunomide is app...
Key objectives in the treatment of multiple sclerosis (MS) include prevention of relapses, a reducti...
Introduction: We have different treatment alternatives for relapsing-remitting multiple sclerosis–RR...
BACKGROUND: The monoclonal antibody ublituximab enhances antibody-dependent cellular cytolysis and p...
Background: Disease-modifying therapy is the standard treatment for patients with multiple sclerosis...
Teriflunomide is an oral disease-modifying therapy approved for treatment of relapsing or relapsing-...
The article discusses the prospects for the use of the new drug teriflunomide for the treatment of p...
AbstractPurposeThe purpose was to summarize US prescribing information for teriflunomide in the trea...
BACKGROUND: Teriflunomide is a new oral disease-modifying therapy for relapsing forms of multiple sc...
Teriflunomide is a new oral disease-modifying therapy for relapsing forms of multiple sclerosis.We c...
Miller, Aaron E O'Connor, Paul Wolinsky, Jerry S Confavreux, Christian Kappos, Ludwig Olsson, Tomas ...
The landscape of the treatment of relapsing–remitting multiple sclerosis is changing fast. Several o...
Teriflunomide is a once-daily oral agent that has been licensed in the EU since August 2013 for the ...
Teriflunomide is a once-daily oral immunomodulator approved for the treatment of relapsing-remitting...
Antonios Bayas,1 Mathias Mäurer2 1Department of Neurology, Klinikum Augsburg, Augsburg, Germany...
Background Therapeutic options for children with multiple sclerosis are scarce. Teriflunomide is app...
Key objectives in the treatment of multiple sclerosis (MS) include prevention of relapses, a reducti...
Introduction: We have different treatment alternatives for relapsing-remitting multiple sclerosis–RR...
BACKGROUND: The monoclonal antibody ublituximab enhances antibody-dependent cellular cytolysis and p...
Background: Disease-modifying therapy is the standard treatment for patients with multiple sclerosis...